Effectiveness of Dasabuvir/ombitasvir/paritaprevir/ritonavir for Hepatitis C Virus in Clinical Practice: A Population-based Observational Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Jul 8

PMID 28686590

Citations 3

Authors

Maya Leventer-Roberts

Ariel Hammerman

Ilan Brufman

Moshe Hoshen

Marius Braun

Yaffa Ashur

Nicky Lieberman

Ran Balicer

Affiliations

Soon will be listed here.

Abstract

Background: Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials.

Aim: To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response.

Methods: Retrospective observational cohort study of all Clalit Health Services members with hepatitis C virus genotype 1 who were dispensed dasabuvir/ombitasvir/paritaprevir/ritonavir from January 1, 2015 to-November 31, 2015.

Results: There were 564 participants during the study period. The average age was 61.9 years, 52.0% were male, and 61.5% were born Eastern/Central Europe or Central Asia. The prevalence of diabetes was 31.7% and 70.3% were overweight/obese. Cirrhosis was present in 41.0% of participants, of whom 52.8% had stage 4 fibrosis. Of the cohort, 416 (74.8%) had follow-up viral load testing at 10 or more weeks after the end of treatment. We report a sustained virological response of 98.8% among those tested.

Conclusions: Treatment with dasabuvir/ombitasvir/paritaprevir/ritonavir demonstrated a near universal effectiveness in achieving a sustained virological response among HCV patients in a large cohort.

Citing Articles

Combination of dasabuvir and PSI-6206 for the treatment of coxsackievirus B3 infection.

Olasunkanmi O, Zhong Z J Virus Erad. 2022; 8(2):100074.

PMID: 35789934 PMC: 9249823. DOI: 10.1016/j.jve.2022.100074.

Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy.

Danilescu C, Sandulescu D, Pirlog M, Streba C, Rogoveanu I Diagnostics (Basel). 2021; 11(12).

PMID: 34943472 PMC: 8700570. DOI: 10.3390/diagnostics11122237.

Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.

Juanbeltz R, Martinez-Baz I, San Miguel R, Goni-Esarte S, Cabases J, Castilla J PLoS One. 2018; 13(10):e0205277.

PMID: 30300395 PMC: 6177189. DOI: 10.1371/journal.pone.0205277.

References

Zeuzem S, Jacobson I, Baykal T, Marinho R, Poordad F, Bourliere M . Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370(17):1604-14. DOI: 10.1056/NEJMoa1401561. View

Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C . ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370(21):1983-92. DOI: 10.1056/NEJMoa1402338. View

Walker D, Pedrosa M, Manthena S, Patel N, Marx S . Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Adv Ther. 2015; 32(11):1117-27. PMC: 4662718. DOI: 10.1007/s12325-015-0258-5. View

Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C . Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015; 163(12):899-907. PMC: 10725568. DOI: 10.7326/M15-0642. View

Backus L, Belperio P, Shahoumian T, Loomis T, Mole L . Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther. 2015; 42(5):559-73. DOI: 10.1111/apt.13300. View

Charlson M, Szatrowski T, Peterson J, Gold J . Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47(11):1245-51. DOI: 10.1016/0895-4356(94)90129-5. View

Ioannou G, Beste L, Chang M, Green P, Lowy E, Tsui J . Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology. 2016; 151(3):457-471.e5. PMC: 5341745. DOI: 10.1053/j.gastro.2016.05.049. View

NajafZadeh M, Andersson K, Shrank W, Krumme A, Matlin O, Brennan T . Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015; 162(6):407-19. DOI: 10.7326/M14-1152. View

Sulkowski M, Eron J, Wyles D, Trinh R, Lalezari J, Wang C . Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015; 313(12):1223-31. DOI: 10.1001/jama.2015.1328. View

10.

Saeed S, Strumpf E, Walmsley S, Rollet-Kurhajec K, Martel-Laferriere V, Gill M . How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. Clin Infect Dis. 2016; 62(7):919-926. PMC: 4787608. DOI: 10.1093/cid/civ1222. View

11.

Wilder J, Muir A . Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. Ther Adv Chronic Dis. 2015; 6(6):314-27. PMC: 4622314. DOI: 10.1177/2040622315603642. View

12.

Fabrizi F, Messa P . Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?. Expert Rev Clin Pharmacol. 2015; 8(6):785-93. DOI: 10.1586/17512433.2015.1086266. View

13.

Feld J, Kowdley K, Coakley E, Sigal S, Nelson D, Crawford D . Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370(17):1594-603. DOI: 10.1056/NEJMoa1315722. View

14.

Maruyama A, Partovi N, Yoshida E, Erb S, Marquez Azalgara V, Hussaini T . A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2015; 32(1):35-41. DOI: 10.1093/ndt/gfv361. View

15.

Ara A, Paul J . New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2016; 11(7):458-66. PMC: 4843024. View

16.

Poordad F, Hezode C, Trinh R, Kowdley K, Zeuzem S, Agarwal K . ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370(21):1973-82. DOI: 10.1056/NEJMoa1402869. View

17.

Backus L, Belperio P, Shahoumian T, Loomis T, Mole L . Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther. 2016; 44(4):400-10. DOI: 10.1111/apt.13696. View

18.

Gutierrez J, Lawitz E, Poordad F . Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015; 22(11):861-70. DOI: 10.1111/jvh.12422. View

19.

Karpati T, Cohen-Stavi C, Leibowitz M, Hoshen M, Feldman B, Balicer R . Towards a subsiding diabetes epidemic: trends from a large population-based study in Israel. Popul Health Metr. 2014; 12(1):32. PMC: 4233034. DOI: 10.1186/s12963-014-0032-y. View

20.

Shmueli A, Bendelac J, Achdut L . Who switches sickness funds in Israel?. Health Econ Policy Law. 2008; 2(Pt 3):251-65. DOI: 10.1017/S1744133107004100. View